**Supplementary Table S1. Baseline characteristics in patients enrolled.**

|  |  |  |
| --- | --- | --- |
| **Baseline characteristics** | **Tepotinib + gefitinib(*n* = 31)** | **Chemotherapy(*n* = 24)** |
| Median age, years (range) | 61 (42–76) | 58.3 (42–82) |
| Sex, n (%) | Female | 20 (64.5) | 12 (50) |
| Male | 11 (35.5) | 12 (50) |
| Smoking status, n (%) | Never  | 21 (67.7) | 16 (66.7) |
| Former | 9 (29.0) | 7 (29.2) |
| Current  | 1 (3.2) | 1 (4.2) |
| ECOG PS, n (%) | 0 | 6 (19.4) | 5 (20.8) |
| 1 | 25 (80.6) | 19 (79.2) |
| MET status, n (%) | *MET*amp | 12 (38.7) | 7 (29.2) |
| *MET* GCN ≥5 | 11 (35.5) | 7 (29.2) |
| *MET*:*CEP7* ≥2 | 7 (22.6) | 6 (25.0) |
| MET IHC 3+ | 19 (61.3) | 15 (62.5) |
| Prior EGFR TKI | TKI, n (%) |  |  |
| Gefitinib | 17 (54.8) | 16 (66.7) |
| Afatinib | 5 (16.1) | 3 (12.5) |
| Erlotinib | 5 (16.1) | 2 (8.3) |
| Icotinib | 4 (12.9) | 3 (12.5) |
| Median duration, months (range) | 11.88 (2.9–54.0) | 12.52 (6.2–46.7) |

Abbreviations: CEP7, centromere of chromosome 7; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; GCN, gene copy number; IHC, immunohistochemistry; MET, mesenchymal–epithelial transition factor; *MET*amp, *MET* amplification; TKI, tyrosine kinase inhibitor.